TSLA
Tesla
-- 422.830 NVDA
NVIDIA
-- 138.105 PLTR
Palantir
-- 73.310 ADBE
Adobe
-- 476.930 AMD
Advanced Micro Devices
-- 130.305 
NEWS
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
Wednesday, 11th December at 6:05 am
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immune Response to the Polymer-lipid in mRNA-LNP Formulations."
Dr. Moreadith will present data on the immunological profile of Serina's proprietary POZ-lipid, a next-generation polymer in development to improve lipid nanoparticle (LNP) formulations.
Wednesday, 11th December at 6:05 am
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immune Response to the Polymer-lipid in mRNA-LNP Formulations."
Dr. Moreadith will present data on the immunological profile of Serina's proprietary POZ-lipid, a next-generation polymer in development to improve lipid nanoparticle (LNP) formulations.
The study demonstrated that POZ-lipid did not induce IgM or IgG antibody responses following repeated administration in an animal model. In contrast, standard PEG-lipids commonly utilized in current LNP technologies elicited robust and sustained IgM and IgG responses. Such anti-PEG antibody responses have been implicated in hypersensitivity reactions, including anaphylaxis and other serious adverse events, in recipients of mRNA-based vaccines (e.g., Pfizer-BioNTech and Moderna).
The absence of an IgM or IgG response to Serina's POZ-lipid is a notable observation that suggests its potential to enable the development of safer and more immunologically compatible LNP formulations.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment